Anti-VEGF Market Size, Share, and Growth Forecast for 2025 - 2032

Table of Content

1. Executive Summary
   1. Global Anti-VEGF Market Snapshot 2025 and 2032
   2. Market Opportunity Assessment, 2025-2032, US$ Bn
   3. Key Market Trends
   4. Industry Developments and Key Market Events
   5. Demand Side and Supply Side Analysis
   6. PMR Analysis and Recommendations
2. Market Overview
   1. Market Scope and Definitions
   2. Value Chain Analysis
   3. Macro-Economic Factors
      1. Global GDP Outlook
      2. Global GDP Outlook
      3. Global economic Growth Forecast
      4. Global Urbanization Growth
      5. Other Macro-economic Factors
   4. Forecast Factors – Relevance and Impact
   5. COVID-19 Impact Assessment
   6. PESTLE Analysis
   7. Porter's Five Forces Analysis
   8. Geopolitical Tensions: Market Impact
   9. Regulatory and Technology Landscape
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Trends
4. Price Trend Analysis, 2019 – 2032
   1. Region-wise Price Analysis
   2. Price by Segments
   3. Price Impact Factors
5. Global Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
   1. Key Highlights
   2. Global Anti-VEGF Market Outlook: Drug
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Bn) Analysis by Drug, 2019-2024
      3. Current Market Size (US$ Bn) Forecast, by Drug, 2025-2032
         1. Small Molecules
            1. Pazopanib
            2. Sunitinib
            3. Sorafenib
            4. Regorafenib
            5. Cabozantinib
            6. Lenvatinib
         2. Biologics
            1. Bevacizumab
            2. Aflibercept
            3. Ramucirumab
      4. Market Attractiveness Analysis: Drug
   3. Global Anti-VEGF Market Outlook: Type
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Bn) Analysis by Type, 2019-2024
      3. Current Market Size (US$ Bn) Forecast, by Type, 2025-2032
         1. VEGF-A Inhibitors
         2. VEGF-B Inhibitors
         3. VEGF-C Inhibitors
         4. Placenta Growth Factor Inhibitors
      4. Market Attractiveness Analysis: Type
   4. Global Anti-VEGF Market Outlook: Disease Indication
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Bn) Analysis by Disease Indication, 2019-2024
      3. Current Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
         1. Oncology
         2. Hematology Disorders
         3. Ophthalmology Disorders
      4. Market Attractiveness Analysis: Disease Indication
   5. Global Anti-VEGF Market Outlook: Distribution Channel
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Bn) Analysis by Distribution Channel, 2019-2024
      3. Current Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
         1. Hospitals
         2. Specialty Clinics
         3. Mail Order Pharmacies
      4. Market Attractiveness Analysis: Distribution Channel
6. Global Anti-VEGF Market Outlook: Region
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis by Region, 2019-2024
   3. Current Market Size (US$ Bn) Forecast, by Region, 2025-2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia & Oceania
      5. Latin America
      6. Middle East & Africa
   4. Market Attractiveness Analysis: Region
7. North America Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
   1. Key Highlights
   2. Pricing Analysis
   3. North America Market Size (US$ Bn) Forecast, by Country, 2025-2032
      1. U.S.
      2. Canada
   4. North America Market Size (US$ Bn) Forecast, by Drug, 2025-2032
      1. Small Molecules
         1. Pazopanib
         2. Sunitinib
         3. Sorafenib
         4. Regorafenib
         5. Cabozantinib
         6. Lenvatinib
      2. Biologics
         1. Bevacizumab
         2. Aflibercept
         3. Ramucirumab
   5. North America Market Size (US$ Bn) Forecast, by Type, 2025-2032
      1. VEGF-A Inhibitors
      2. VEGF-B Inhibitors
      3. VEGF-C Inhibitors
      4. Placenta Growth Factor Inhibitors
   6. North America Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
      1. Oncology
      2. Hematology Disorders
      3. Ophthalmology Disorders
   7. North America Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals
      2. Specialty Clinics
      3. Mail Order Pharmacies
8. Europe Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
   1. Key Highlights
   2. Pricing Analysis
   3. Europe Market Size (US$ Bn) Forecast, by Country, 2025-2032
      1. Germany
      2. Italy
      3. France
      4. U.K.
      5. Spain
      6. Russia
      7. Rest of Europe
   4. Europe Market Size (US$ Bn) Forecast, by Drug, 2025-2032
      1. Small Molecules
         1. Pazopanib
         2. Sunitinib
         3. Sorafenib
         4. Regorafenib
         5. Cabozantinib
         6. Lenvatinib
      2. Biologics
         1. Bevacizumab
         2. Aflibercept
         3. Ramucirumab
   5. Europe Market Size (US$ Bn) Forecast, by Type, 2025-2032
      1. VEGF-A Inhibitors
      2. VEGF-B Inhibitors
      3. VEGF-C Inhibitors
      4. Placenta Growth Factor Inhibitors
   6. Europe Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
      1. Oncology
      2. Hematology Disorders
      3. Ophthalmology Disorders
   7. Europe Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals
      2. Specialty Clinics
      3. Mail Order Pharmacies
9. East Asia Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
   1. Key Highlights
   2. Pricing Analysis
   3. East Asia Market Size (US$ Bn) Forecast, by Country, 2025-2032
      1. China
      2. Japan
      3. South Korea
   4. East Asia Market Size (US$ Bn) Forecast, by Drug, 2025-2032
      1. Small Molecules
         1. Pazopanib
         2. Sunitinib
         3. Sorafenib
         4. Regorafenib
         5. Cabozantinib
         6. Lenvatinib
      2. Biologics
         1. Bevacizumab
         2. Aflibercept
         3. Ramucirumab
   5. East Asia Market Size (US$ Bn) Forecast, by Type, 2025-2032
      1. VEGF-A Inhibitors
      2. VEGF-B Inhibitors
      3. VEGF-C Inhibitors
      4. Placenta Growth Factor Inhibitors
   6. East Asia Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
      1. Oncology
      2. Hematology Disorders
      3. Ophthalmology Disorders
   7. East Asia Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals
      2. Specialty Clinics
      3. Mail Order Pharmacies
10. South Asia & Oceania Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. South Asia & Oceania Market Size (US$ Bn) Forecast, by Country, 2025-2032
       1. India
       2. Southeast Asia
       3. ANZ
       4. Rest of SAO
    4. South Asia & Oceania Market Size (US$ Bn) Forecast, by Drug, 2025-2032
       1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
       2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
    5. South Asia & Oceania Market Size (US$ Bn) Forecast, by Type, 2025-2032
       1. VEGF-A Inhibitors
       2. VEGF-B Inhibitors
       3. VEGF-C Inhibitors
       4. Placenta Growth Factor Inhibitors
    6. South Asia & Oceania Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
       1. Oncology
       2. Hematology Disorders
       3. Ophthalmology Disorders
    7. South Asia & Oceania Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
       1. Hospitals
       2. Specialty Clinics
       3. Mail Order Pharmacies
11. Latin America Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. Latin America Market Size (US$ Bn) Forecast, by Country, 2025-2032
       1. Brazil
       2. Mexico
       3. Rest of LATAM
    4. Latin America Market Size (US$ Bn) Forecast, by Drug, 2025-2032
       1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
       2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
    5. Latin America Market Size (US$ Bn) Forecast, by Type, 2025-2032
       1. VEGF-A Inhibitors
       2. VEGF-B Inhibitors
       3. VEGF-C Inhibitors
       4. Placenta Growth Factor Inhibitors
    6. Latin America Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
       1. Oncology
       2. Hematology Disorders
       3. Ophthalmology Disorders
    7. Latin America Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
       1. Hospitals
       2. Specialty Clinics
       3. Mail Order Pharmacies
12. Middle East & Africa Anti-VEGF Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. Middle East & Africa Market Size (US$ Bn) Forecast, by Country, 2025-2032
       1. GCC Countries
       2. South Africa
       3. Northern Africa
       4. Rest of MEA
    4. Middle East & Africa Market Size (US$ Bn) Forecast, by Drug, 2025-2032
       1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
       2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
    5. Middle East & Africa Market Size (US$ Bn) Forecast, by Type, 2025-2032
       1. VEGF-A Inhibitors
       2. VEGF-B Inhibitors
       3. VEGF-C Inhibitors
       4. Placenta Growth Factor Inhibitors
    6. Middle East & Africa Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
       1. Oncology
       2. Hematology Disorders
       3. Ophthalmology Disorders
    7. Middle East & Africa Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
       1. Hospitals
       2. Specialty Clinics
       3. Mail Order Pharmacies
13. Competition Landscape
    1. Market Share Analysis, 2024
    2. Market Structure
       1. Competition Intensity Mapping
       2. Competition Dashboard
    3. Company Profiles
       1. Pfizer Inc.
          1. Company Overview
          2. Product Portfolio/Offerings
          3. Key Financials
          4. SWOT Analysis
          5. Company Strategy and Key Developments
       2. Bayer AG
       3. Novartis AG
       4. Sanofi SA
       5. Exelixis Inc.
       6. Eisai Co. Ltd.
       7. Amgen Inc.
       8. F. Hoffmann-La Roche Ltd.
       9. Eli Lilly and Company
       10. Amneal Pharmaceuticals Inc.
       11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
       12. Takeda Pharmaceutical Co. Ltd.
       13. Sino Biopharma
       14. HUTCHMED
14. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations